Connection

Jean-Charles Soria to Bevacizumab

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Bevacizumab.
Jean-Charles Soria
Connection Strength
0.626
Bevacizumab
  1. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. Eur J Cancer. 2017 11; 86:186-196.
    View in: PubMed
    Score: 0.626
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.